An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Summary

This open-label, multicenter expanded access program (EAP) is designed to provide emicizumab to eligible participants with hemophilia A with factor VIII (FVIII) inhibitors before it is commercially available in the United States for the indication of hemophilia A with FVIII inhibitors. Discontinuation may occur earlier if participant or physician decides to discontinue treatment or the sponsor discontinues emicizumab clinical development.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications